Darusentan

Last updated
Darusentan
Darusentan.svg
Clinical data
Routes of
administration 		Oral
ATC code
  • none
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Metabolism Hepatic
Elimination half-life 12.5 hours
Identifiers
  • (2S)-2-(4,6-Dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.126.841 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C22H22N2O6
Molar mass 410.426 g·mol−1
3D model (JSmol)
  • COC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)OC
  • InChI=1S/C22H22N2O6/c1-27-17-14-18(28-2)24-21(23-17)30-19(20(25)26)22(29-3,15-10-6-4-7-11-15)16-12-8-5-9-13-16/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1 X mark.svgN
  • Key:FEJVSJIALLTFRP-LJQANCHMSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. [1] Gilead Colorado, a subsidiary of Gilead Sciences, [2] under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.

In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field. [3]

In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study, but was terminated because the study did not reach its primary endpoints. [4]

See also

References

  1. ↑ Enseleit F, Lüscher TF, Ruschitzka F (August 2010). "Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension" (PDF). Therapeutic Advances in Cardiovascular Disease. 4 (4): 231–40. doi:10.1177/1753944710373785. PMID   20660536. S2CID   22533124.
  2. ↑ Gilead Sciences [ permanent dead link ]
  3. ↑ "Darusentan - Gilead Sciences". Adis Insight. Springer Nature Switzerland AG.
  4. ↑ Clinical trial number NCT00389675 for "DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension (Darusentan)" at ClinicalTrials.gov


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.